Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688246 · ClinicalTrials.gov registry record
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
A clinical trial, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- 238
- Enrollment target
NCT00688246: Completed study, sponsored by NCIC Clinical Trials Group.
NCT00688246 is a clinical trial that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 238 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00688246 has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- 238 participants
- Enrollment target
Study Summary
RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more comfortably. PURPOSE: This research study is measuring bone mineral density in postmenopausal women at increased risk of developing breast cancer who are receiving exemestane on clinical trial CAN-NCIC-MAP3.
Interventions
- OTHER biologic sample preservation procedure
- PROCEDURE dual x-ray absorptometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2008-07-10 |
| Est. Completion | 2013-01-10 |
What the finished NCT00688246 record still lists
NCT00688246 is an observational study that tracks outcomes without assigning an intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which biologic sample preservation procedure is the first listed.
NCT00688246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00688246 about?
NCT00688246 is a clinical study titled "Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3". RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more comfortably. PURPOSE: This research study is measuring bone mineral density i...
What is the current status of trial NCT00688246?
This trial is currently completed. The enrollment target is 238 participants. The study started on 2008-07-10. Estimated completion is 2013-01-10.
What interventions are being tested in trial NCT00688246?
The interventions under investigation include: biologic sample preservation procedure (OTHER), dual x-ray absorptometry (PROCEDURE).
Who is sponsoring clinical trial NCT00688246?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI